Key Points
- Roivant CEO Eric Venker sold 200,000 shares on December 23 at an average price of $22.45 for about $4.49 million, leaving him with 1,611,749 shares — an 11.04% reduction in his stake.
- The December sale is part of sustained insider selling since October, including multiple large disposals (several 200k+ trades), cumulatively generating tens of millions of dollars in proceeds.
- ROIV was trading near $21.70 (50-day MA $20.65, 52-week high $23.47) and carries an analyst consensus of "Moderate Buy" with an average price target of $25.19.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 75,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00. Following the sale, the chief executive officer owned 1,654,597 shares of the company's stock, valued at $37,278,070.41. This trade represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Eric Venker also recently made the following trade(s):
- On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total value of $4,490,000.00.
- On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.85, for a total value of $4,170,000.00.
- On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.22, for a total value of $4,044,000.00.
- On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total value of $2,020,211.08.
- On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The stock was sold at an average price of $16.93, for a total value of $7,020,583.19.
- On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The shares were sold at an average price of $17.05, for a total transaction of $5,426,708.10.
- On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total transaction of $336,813.75.
- On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The stock was sold at an average price of $16.30, for a total transaction of $1,710,522.00.
- On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The stock was sold at an average price of $16.20, for a total transaction of $2,245,352.40.
- On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total transaction of $2,800,610.64.
Roivant Sciences Trading Down 2.4%
NASDAQ ROIV opened at $21.70 on Tuesday. The company has a market cap of $15.09 billion, a price-to-earnings ratio of -38.75 and a beta of 1.22. The company has a 50 day moving average of $20.65 and a 200-day moving average of $15.59. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $23.47.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ROIV. Weiss Ratings upgraded Roivant Sciences from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Saturday, October 25th. Leerink Partners boosted their price target on Roivant Sciences from $29.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, December 15th. HC Wainwright upped their price objective on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, December 12th. Guggenheim reiterated a "buy" rating and set a $28.00 price objective on shares of Roivant Sciences in a research note on Thursday, December 18th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $25.19.
Read Our Latest Analysis on Roivant Sciences
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. Amundi boosted its stake in shares of Roivant Sciences by 18.1% during the first quarter. Amundi now owns 398,729 shares of the company's stock valued at $3,991,000 after purchasing an additional 61,214 shares in the last quarter. Inspire Investing LLC bought a new position in Roivant Sciences in the 1st quarter valued at approximately $303,000. Valeo Financial Advisors LLC acquired a new stake in Roivant Sciences during the 2nd quarter worth approximately $1,145,000. IFG Advisory LLC bought a new stake in Roivant Sciences during the 2nd quarter worth approximately $255,000. Finally, Franklin Resources Inc. acquired a new position in Roivant Sciences in the 2nd quarter valued at approximately $997,000. Institutional investors own 64.76% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
